Akero Publishes 96-Week Phase 2b HARMONY Trial Results In The Lancet Showing Near Complete MASH Reversal In One-Third Of Patients On 50mg EFX

Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced publication of 96-week results from the Phase 2b HARMONY trial in The Lancet.

The publication reports final results from HARMONY, a 96-week multicenter, randomized, double-blind, placebo-controlled trial that evaluated efruxifermin (EFX) in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and moderate (F2) or advanced (F3) fibrosis. Continued treatment with EFX from 24 to 96 weeks resulted in more participants exhibiting improvements in fibrosis and MASH, such that there was near complete reversal of disease in almost one-third of participants treated with the 50mg dose of EFX. EFX-treated participants also exhibited improvements in markers of liver injury and whole-body metabolic health.